Endra Life Sciences Inc (NDRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -11,508 | -7,359 | -5,005 | -2,776 | -10,060 |
| Depreciation Amortization | 206 | 160 | 106 | 56 | 276 |
| Other Working Capital | 134 | -77 | 154 | 107 | -923 |
| Other Operating Activity | 3,767 | 1,391 | 518 | 469 | 1,159 |
| Operating Cash Flow | $-7,401 | $-5,885 | $-4,228 | $-2,144 | $-9,549 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -13 | -13 | -13 | -24 | -25 |
| Investing Cash Flow | $-13 | $-13 | $-13 | $-24 | $-25 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -29 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 7,837 | 7,837 | 7,836 | 497 | 7,518 |
| Other Financing Activity | 0 | -29 | -29 | -29 | 0 |
| Financing Cash Flow | $7,809 | $7,809 | $7,807 | $469 | $7,518 |
| Beginning Cash Position | 2,834 | 2,834 | 2,834 | 2,834 | 4,889 |
| End Cash Position | 3,230 | 4,745 | 6,401 | 1,135 | 2,834 |
| Net Cash Flow | $396 | $1,911 | $3,567 | $-1,699 | $-2,055 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,401 | -5,885 | -4,228 | -2,144 | -9,549 |
| Capital Expenditure | -16 | -16 | -16 | -27 | -34 |
| Free Cash Flow | -7,417 | -5,901 | -4,244 | -2,171 | -9,583 |